Table 1.
HCV Positive Liver and Kidney Transplant Recipient Treatment Patterns
| Liver Pre-DAA | HCV D+/R+ | HCV D-/R+ | HCV D-/R- | HCV D+/R- |
|---|---|---|---|---|
| Total subjects | 1,132 | 14,640 | 20,864 | 0 |
| PCD eligibility at Tx | 926 | 11,348 | 15,902 | 0 |
| 1 year PCD eligibility post-Tx | 985 | 12,488 | 18,433 | 0 |
| HCV Rx: 3 months post-Tx | 3 | 98 | 3 | 0 |
| HCV Rx: 1 year post-Tx | 59 | 820 | 29 | 0 |
| HCV Rx: post-Tx | 335 | 3,907 | 153 | 0 |
| Listing to Tx in days (Mean) | 303 | 282 | 225 | NA |
|
Liver Post-DAA | ||||
| Total subjects | 1,166 | 6,254 | 14,320 | 133 |
| PCD eligibility at transplant | 890 | 4,908 | 10,716 | 85 |
| 1 year PCD eligibility post-Tx | 483 | 3,183 | 6,071 | 47 |
| HCV Rx: 3 months post-Tx | 47 | 176 | 6 | 1 |
| HCV Rx: 1 year post-Tx | 155 | 614 | 26 | 5 |
| HCV Rx: post-Tx | 181 | 793 | 31 | 11 |
| Listing to Tx in days (Mean) | 328 | 336 | 241 | 315 |
| Kidney Pre-DAA | HCV D+/R+ | HCV D-/R+ | HCV D-/R- | HCV D+/R- |
| Total subjects | 1,377 | 3,173 | 95,715 | 232 |
| PCD eligibility at transplant | 1,066 | 2,480 | 75,378 | 184 |
| 1 year PCD eligibility post-Tx | 1,256 | 2,925 | 89,704 | 212 |
| HCV Rx: 3 months post-Tx | 0 | 2 | 4 | 0 |
| HCV Rx: 1 year post-Tx | 11 | 9 | 6 | 1 |
| HCV Rx: post-Tx | 215 | 298 | 77 | 12 |
| Listing to Tx in days (Mean) | 395 | 826 | 708 | 411 |
| Kidney Post-DAA | ||||
| Total subjects | 1,083 | 1,608 | 54,412 | 273 |
| PCD eligibility at transplant | 852 | 1,247 | 42,892 | 157 |
| 1 year PCD eligibility post-Tx | 482 | 756 | 26,383 | 82 |
| HCV Rx: 3 months post-Tx | 19 | 19 | 2 | 1 |
| HCV Rx: 1 year post-Tx | 144 | 82 | 13 | 11 |
| HCV Rx: post-Tx | 181 | 119 | 25 | 11 |
| Listing to Tx in days (Mean) | 396 | 871 | 749 | 384 |
Abbreviations: D/R; donor/recipient hepatitis status; DAA, direct acting antiviral; HCV, hepatitis C virus; Rx, treatment for HCV; PCD, pharmaceutical claims data; Tx, transplant.